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Commonly used liver function tests do not always normalize after successful attenuation of 
congenital extrahepatic portosystemic shunts (EHPSS) in dogs. In human medicine, the 
hepatic metabolism of lidocaine is used as a dynamic liver function test. The advantages of 
the use of lidocaine are its short elimination half‐life and its high hepatic extraction ratio, that 
is blood flow dependent. This study aimed to assess whether the dynamic 
lidocaine/monoethylglycylxylidide (MEGX) liver function test would be a useful test to 
determine postoperative EHPSS closure. 
Dogs with EHPSS were prospectively enrolled. The lidocaine/MEGX test was performed at 
diagnosis, and at 1, 3, and 6 months postoperatively. At each time point, 1 mg/kg lidocaine 
was injected intravenously and blood samples were taken before (T0) and 15 minutes after 
injection (T15). Plasma concentrations of lidocaine and its metabolite MEGX were 
determined using a validated LC‐MS/MS method. Three months postoperatively, a 
transsplenic portal scintigraphy was performed to determine EHPSS closure. 
At T15, dogs with a closed EHPSS (n = 16) had significantly higher median MEGX 
concentrations at postoperative time points compared to diagnosis (P < 0.001), whereas no 
significant differences were noticed for dogs with persistent shunting (n = 5). Sensitivity and 
specificity to determine shunt closure were 96.2% and 82.8%, respectively.  
The lidocaine/MEGX test is a promising, rapid and non‐invasive dynamic liver function test 
that seems helpful to determine EHPSS closure in dogs. Dogs with a normal fasted ammonia 
concentration but high MEGX concentration at T15 after surgical attenuation are very likely 
to have a closed EHPSS, and therefore additional medical imaging to determine shunt closure 
is not of added value in the vast majority of cases. In dogs with persistent shunting, advanced 
medical imaging remains important to differentiate between persistent EHPSS and multiple 
acquired portosystemic shunts. Further studies in a larger cohort of dogs are warranted to 
consolidate these promising findings. 
Disclosures: This study was funded by the Gesellschaft zur Förderung Kynologischer 
Forschung e.V.  
 
